Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus

Journal of Clinical Investigation

Volumn 123, Issue 12, 2013, Pages 5135-5145

  Price, Jordan V ^a,b   Haddon, David J ^a,b   Kemmer, Dodge ^a,b   Delepine, Guillaume ^a,b   Mandelbaum, Gil ^a,b   Jarrell, Justin A ^a,b   Gupta, Rohit ^a,b   Balboni, Imelda ^a   Chakravarty, Eliza F ^c   Sokolove, Jeremy ^a,d   Shum, Anthony K ^e   Anderson, Mark S ^f   Cheng, Mickie H ^f   Robinson, William H ^a,d   Browne, Sarah K ^g   Holland, Steven M ^g   Baechler, Emily C ^h   Utz, Paul J ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Institute for Immunity Transplantation and Infection Operations   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e Department of Medicine   (United States)

^f UCSF Diabetes Center   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 27; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 9;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATORY DISEASE; MYCOBACTERIOSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MICROARRAY; SERUM FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODY SPECIFICITY; AUTOANTIBODIES; AUTOANTIGENS; B-CELL ACTIVATING FACTOR; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MYCOBACTERIUM INFECTIONS; POLYENDOCRINOPATHIES, AUTOIMMUNE; PROTEIN ARRAY ANALYSIS; RECOMBINANT PROTEINS;

EID: 84890058195     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70231     Document Type: Article

References (51)

1. Morimoto AM, et al. Association of endogenous antiinterferon- α autoantibodies with decreased interferon- pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63(8):2407-2415
2. Uchida K, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med. 2007;356(6):567-579
3. Doffinger R, et al. Autoantibodies to interferongamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis. 2004;38(1):e10-e14
4. Hoflich C, et al. Naturally occurring anti-IFNgamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood. 2004;103(2):673-675
5. Patel SY, et al. Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol. 2005;175(7):4769-4776.
6. Browne SK, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med. 2012; 367(8):725-734
7. Meager A, et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 2006;3(7):e289
8. Puel A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med. 2010;207(2):291-297
9. Kisand K, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med. 2010;207(2):299-308
10. Hellmich B, Csernok E, Schatz H, Gross WL, Schnabel A. Autoantibodies against granulocyte colonystimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum. 2002;46(9):2384-2391
11. Burbelo PD, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010; 116(23):4848-4858
12. Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis. 2010;10(12):875-885
13. Browne SK, Holland SM. Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol. 2010;10(6):534-541
14. Ding L, Mo A, Jutivorakool K, Pancholi M, Holland SM, Browne SK. Determination of human anticytokine autoantibody profiles using a particle-based approach. J Clin Immunol. 2012;32(2):238-245
15. Robinson WH, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002;8(3):295-301
16. Hueber W, et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2005;52(9):2645-2655
17. Price JV, et al. On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat Med. 2012; 18(9):1434-1440
18. Bauer JW, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006; 3(12):2274-2284
19. Ray S, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007;13(11):1359-1362
20. Britschgi M, Wyss-Coray T. Blood protein signature for the early diagnosis of Alzheimer disease. Arch Neurol. 2009;66(2):161-165
21. Hilbert DM, et al. BLyS, a novel member of the tumor necrosis factor family and potent B lymphocyte stimulator. Blood. 1999;94(2):584A-584A
22. Mackay F, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999; 190(11):1697-1710
23. Stohl W. SLE - systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther. 2003; 5(3):136-138
24. Lesley R, et al. Reduced competitiveness of autoantigen- engaged B cells due to increased dependence on BAFF. Immunity. 2004;20(4):441-453
25. Thien M, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20(6):785-798
26. Pers JO, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005;1050:34-39
27. McClements M, Williams S, Ball C, Bristow A, Wadhwa M, Meager A. A novel bioassay for B-cell activating factor (BAFF) based on expression of a BAFF-receptor ectodomain-tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-2 endodomain fusion receptor in human rhabdomyosarcoma cells. J Immunol Methods. 2008; 337(1):63-70
28. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus. 2010; 19(9):1012-1019
29. Wallace DJ, et al. A phase 2, randomized, doubleblind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168-1178
30. Fairfax K, Mackay IR, Mackay F. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus. IUBMB Life. 2012;64(7):595-602
31. Aaltonen J, et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. 1997;17(4):399-403
32. Anderson MS, Su MA. Aire and T cell development. Curr Opin Immunol. 2011;23(2):198-206
33. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98(9):5116-5121
34. Petri M. Hopkins Lupus cohort - 1999 update. Rheum Dis Clin North Am. 2000;26(2):199-213
35. Wallace DJ, Hahn B, Dubois EL. Dubois' Lupus Erythematosus. Philadelphia, Pennsylvania, USA: Lippincott Williams and Wilkin; 2007
36. Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol. 2002; 2(7):465-475
37. Doreau A, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol. 2009;10(7):778-785
38. Boneparth A, Davidson A. B-cell activating factor targeted therapy and lupus. Arthritis Res Ther. 2012; 14(suppl 4):S2
39. Shum K, Askanase A. Belimumab and the clinical data. Curr Rheum Rep. 2012;14(4):310-317
40. Bezalel S, Asher I, Elbirt D, Sthoeger ZM. Novel biological treatments for systemic lupus erythematosus: current and future modalities. Isr Med Assoc J. 2012; 14(8):508-514
41. Baechler EC, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-2615
42. Rönnblom L, Eloranta ML. The interferon signature in autoimmune diseases. Curr Opin Rheumatol. 2013; 25(2):248-253
43. Bauer JW, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity A validation study. Arthritis Rheum. 2009; 60(10):3098-3107
44. La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin Immunol. 2013;148(3):322-327
45. van der Meide PH, Schellekens H. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy. 1997;10(1):39-48
46. Watanabe M, et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. Febs Lett. 2007; 581(10):2017-2021
47. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virusspecific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity. 2013; 38(2):373-383
48. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol. 2012;22(17):R733-R740
49. Kattah MG, Alemi GR, Thibault DL, Balboni I, Utz PJ. A new two-color Fab labeling method for autoantigen protein microarrays. Nat Methods. 2006; 3(9):745-751
50. Tabakman SM, et al. Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range. Nat Commun. 2011; 2:466
51. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(suppl 1):S49-S52